Wall Street analyst price targets, ratings consensus & upside potential · Updated Jun 5, 2026
Last 12 months price action with 12-month analyst target path
As of June 12, 2026, Q32 Bio Inc. (QTTB) has a Wall Street consensus price target of $13.50, based on estimates from 8 covering analysts. With the stock currently trading at $12.70, this represents a potential upside of +6.3%. The company has a market capitalization of $162M.
Analyst price targets range from a low of $13.00 to a high of $14.00, representing a 7% spread in expectations. The median target of $13.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 3 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, QTTB trades at a trailing P/E of 5.2x. Analysts expect EPS to grow -177.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $18.95, with bear and bull scenarios of $13.26 and $349.02 respectively. Model confidence stands at 26/100, suggesting limited visibility into future performance.
Total return calculator · dividends reinvested
Calculate ReturnsDollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationSide-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowQuick answers to the most common questions about buying QTTB stock.
The consensus price target for QTTB is $13.5, close to the current price of $12.7 (6.3% implied move). Based on 8 analyst estimates, the stock appears fairly valued near current levels.
QTTB has a consensus rating of "Hold" based on 8 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $13.5 implies 6.3% upside from current levels.
QTTB's current price is $12.7 with a consensus target of $13.5 (6.3% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $14 for QTTB, while the most conservative target is $13. The consensus of $13.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $349 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
QTTB is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month QTTB stock forecast based on 8 Wall Street analysts shows a consensus price target of $13.5, with estimates ranging from $13 (bear case) to $14 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $19, with bear/bull scenarios of $13/$349.
Our quantitative valuation model calculates QTTB's fair value at $19 (base case), with a bear case of $13 and bull case of $349. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 26/100.
QTTB appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $13.5 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
QTTB analyst price targets range from $13 to $14, a 7% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $13.5 consensus represents the middle ground. Our model's $13-$349 range provides an independent fundamental perspective.